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Site-directed mutagenesis to the 20 natural amino
acids becomes a limitation when evaluating subtle
perturbations of an amino acid side chain within a
protein. To further the study of Src homology 2
(SH2) domain ligand binding, we have developed
a system allowing its semisynthesis from three frag-
ments by native chemical ligation. We have replaced
a key lysine residue with lysyl derivatives possessing
progressively shorter aliphatic side chains. Biophys-
ical characterization of these SH2 domain analogs
has allowed for the first time a systematic dissection
of the side chain length contribution from a lysine
residue to ligand binding. We show that the speci-
ficity of the SH2 domain of the Src kinase can be
altered by incorporation of such lysyl derivatives,
thereby demonstrating the potential of the technique
for the development of SH2 domain-based research
tools and therapeutics.INTRODUCTION
SH2 domains are modular interaction domains of 100 amino
acids that play fundamental roles in eukaryotic cell signaling
(Kuriyan and Cowburn, 1997; Pawson, 1994; Pawson and
Nash, 2003). The human genome consists of 120 different SH2
domains residing within 110 distinct proteins (Liu et al., 2006).
They are dedicated to the recognition of tyrosine phosphorylated
sequence motifs and regulate a number of essential cellular pro-
cesses. Many signaling pathways intersect with SH2 domains,
making them potential therapeutic targets, and mutations
directly within SH2 domains are being progressively identified
as disease associated (Lappalainen et al., 2008; Waksman
et al., 2004). The Src SH2 domain resides within the protein
tyrosine kinase Src and is involved in its recruitment and autore-
gulation of catalytic activity, thereby playing a pivotal role in its
function (Cooper et al., 1986; Luttrell et al., 1988; Xu et al.,
1997). Tyrosine phosphorylation by Src leads to cell signal prop-
agation, and elevated levels of Src kinase activity have been
directly implicated with cancer (Frame, 2002; Yeatman, 2004).
It has also been shown that the isolated Src SH2 domain alone274 Chemistry & Biology 17, 274–284, March 26, 2010 ª2010 Elseviecan elicit significant cellular responses such as halting of the
cell cycle and enlargement of focal adhesions (Twamley-Stein
et al., 1993; Avizienyte et al., 2002). The latter is a consequence
of the SH2 domain’s role in forming signaling complexes at the
sites of focal adhesion proteins (Burnham et al., 2000; McLean
et al., 2005). However, the precise role of Src during the various
stages of tumorigenesis is still poorly defined (Yeatman, 2004).
This is likely to be a result of the many different biological Src
SH2 domain ligands that all bind with high affinity. Interestingly,
Src knockout mice demonstrate only one phenotype, that being
osteopetrosis (Boyce et al., 1992). This is due to a defect in the
formation of the so-called ruffled border on osteoclasts
rendering them ineffective at bone resorption. The significance
of the noncatalytic regions of Src on this phenotype has been
highlighted because the normal phenotype can be rescued by
transgenic expression of kinase-deficient Src (Schwartzberg
et al., 1997). These findings have provided impetus for the devel-
opment of Src SH2 domain binding inhibitors that could be used
to treat numerous degenerative bone disorders such as osteo-
porosis, Paget’s disease, osteolytic bone metastasis, and hypo-
calcaemia associated with malignancy. Despite considerable
investments into developing Src SH2 domain inhibitors, the
broad specificity of Src family SH2 domains coupled with the
strict requirement for a highly charged phosphomimetic has
hindered progress and has largely been abandoned by pharma-
ceutical companies (Bradshaw and Waksman, 2002). However,
inhibitors with therapeutic promise have been developed, and
some even confer bone-targeting properties ensuring concen-
trations are localized at the osteoclast-bone interface (Shake-
speare et al., 2000; Violette et al., 2000).
Previous attempts to engineer SH2 domains with altered or
enhanced specificity have been met with unpredictable
enthalpy-entropy compensation effects (Lubman andWaksman,
2002; Taylor et al., 2008), and library-based approaches only
identified variants that had dual specificity, thus retaining affinity
for the original ligand scaffold (Malabarba et al., 2001). There-
fore, there remains a need for an unequivocal understanding of
the Src SH2 domain’s mode of ligand recognition. These points
gave us impetus to attempt to rationally engineer SH2 domain
analogs, by unnatural amino acid incorporation, that had
genuine altered specificity and that could find application as
research tools. Furthermore, protein therapeutics are becoming
increasingly attractive (Leader et al., 2008), and such SH2
domain analogs may find application here, particularly whenr Ltd All rights reserved
Figure 1. Src SH2 Domain Structure, Phosphopeptide Binding Site, and Incorporated Unnatural Lysine Derivatives
(A) Cartoon representation of the Src SH2 domain bound to a high-affinity pYEEI peptide (stick notation). The various secondary structural elements of the protein
are labeled in accordance with Eck et al. (1993).
(B) Cartoon representation of the binding site of the Src SH2 domain. Key protein residues are depicted in stick notation. The phosphopeptide is in stick notation
and colored blue. The +1 Glu residue of the phosphopeptide lies almost parallel with the side chain of LysBD3 providing the potential for hydrophobic and elec-
trostatic contacts with each other.
(C) Lysine and lysyl derivatives: Orn, Dab, and Dap.
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Engineered Src SH2 Domain with Altered Specificitytheir pharmacokinetic profile can be improved by polymer
attachment (Kochendoerfer, 2005), which could help to address
the shortcomings of Src SH2 domain inhibitor development.
The Src SH2 domain consists of a central antiparallel b sheet
flanked by two a helices (Figure 1A). The binding site consists
of a region responsible for high-affinity phosphotyrosine (pTyr
or pY) binding and an extended region, termed ‘‘specificity
determining region’’ (Waksman et al., 1993). Specificity is
achieved by cumulative interactions with the 3 residues
C-terminal to the ligand’s pTyr (termed ‘‘+1, +2, and +3 resi-
dues’’) (Songyang et al., 1993; Waksman et al., 1993). Songyang
et al. revealed that the pYEEI phosphopeptide motif binds with
the highest affinity to the Src SH2 domain. One of themost signif-
icant protein residues involved in specificity is LysbD3
(Figure 1B) (Bradshaw et al., 2000). In the structure of the Src
SH2 domain-pYEEI complex, this residue lies within close
proximity of the +1 glutamate (+1-Glu) of the pYEEI motif, sug-
gesting that binding of +1-Glu is due to electrostatic interactions
with LysbD3 (see Figure 1B, where the epsilon amino group of
the Lys side chain is within 3.2 to 3.8 A˚ of the carboxylic groupChemistry & Biology 17, 2of the ligand’s +1 Glu). However, this explanation turned out
to be oversimplistic when it was realized that a mutation of
+1-Glu to Ala in the pYEEI ligand had a negligible effect on
binding to the wild-type SH2 domain (Bradshaw and Waksman,
1999), whereas a LysbD3Ala SH2 domain mutant exhibited a
significantly decreased affinity for the pYEEI peptide (Bradshaw
et al., 2000). Subsequently, it was shown that the decreased
affinity displayed by the LysbD3Ala mutant was caused by
a network of acidic residues further afield (AspbC8 and AspCD2)
that exert a repulsive force on the +1-Glu in the absence of
LysbD3 in the LysbD3Ala mutant (Figure 1B) (Lubman and
Waksman, 2002). Thus, in the wild-type, the role of LysbD3 is
to counter the negative electrostatic potential emanating
from AspbC8 and AspCD2 rather than neutralizing the charge
of +1-Glu. This also explained why little change in binding affinity
was observed when mutating the +1-Glu to a series of residues
including Asp and Ala (Bradshaw and Waksman, 1999).
The complexity of the role of LysbD3 in +1 residue binding led
us to consider the bD3, bC8, and CD2 positions in the SH2
domain as potential sites for engineering altered binding affinity74–284, March 26, 2010 ª2010 Elsevier Ltd All rights reserved 275
Figure 2. Three-Fragment Approach to Semisynthesis of the Src
SH2 Domain
The small size of the synthetic cassette (green) allowed rapid and facile
solid-phase synthesis of peptides which could be used to incorporate
unnatural amino acids into the bD strand of the ‘‘specificity determining’’
region. The C-terminal aCys peptide (orange) was prepared by CNBr cleavage
of a biosynthetic precursor and the N-terminal thioester peptide (red) was
prepared by intein-mediated thiolysis of a biosynthetic fusion protein.
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Engineered Src SH2 Domain with Altered Specificityand specificity. Thus, AspbC8 and AspCD2 were mutated to Ala,
resulting in a 2-fold increase in pYEEI binding affinity, possibly
due to an increased electrostatic interaction of +1-Glu with
LysbD3 (Lubman and Waksman, 2002). We also hypothesized
that reduction of the aliphatic portion of LysbD3 residue would
result in a weaker interaction with AspbC8 and AspCD2, thereby
allowing the positive charge at the tip of the shorter aliphatic
chain to bemore easily directed toward and interact with a nega-
tively charged residue at the +1 position of a phosphopeptide
ligand. We further hypothesized that, because the tip of +1-Glu
reaches out slightly beyond LysbD3 in the Src SH2 domain-
pYEEI complex crystal structure (see Figure 1B), a shorter
LysbD3 side chain would more easily be directed to a shorter
acid at the +1 position, Asp for example. This would result in
a change of binding specificity.
Here we report the engineering and binding thermodynamics
of Src SH2 domains with progressively shorter lysine side chains
at the bD3 position. Generation of such mutants was only
possible using a semisynthetic route. Thus, in this report, we first
present the semisynthesis of the Src SH2 domain. We also show
that a three fragment semisynthesis of a relatively small domain
can be achieved without extensive synthetic peptide synthesis.
We then describe the preparation and characterization of276 Chemistry & Biology 17, 274–284, March 26, 2010 ª2010 Elseviesemisynthetic Src SH2 domain analogs containing the unnatural
amino acids ornithine (Orn), diaminobutyric acid (Dab), and
diaminopropionic acid (Dap) (Figure 1C) at the bD3 position.
This allows us to report for the first time the significance of
the length of the aliphatic side chain of a lysine residue in
protein-ligand specificity, and Src SH2 domain phosphopeptide
recognition in particular. We show that fine-tuning of the speci-
ficity-determining region of the Src SH2 domain by incorporation
of Dab enables an altered specificity and 5-fold enhancement
in binding affinity for a peptide that possesses Asp at the +1
position. This affinity also surpasses that of the wild-type SH2
domain interaction with the pYEEI motif by 2-fold. This study
also resolves an outstanding question regarding the hydro-
phobic contribution of the aliphatic chain of the Lys residues to
the free energy of macromolecular interactions in general, and
shows that the electrostatic interaction between lysyl derivatives
and an acidic +1 ligand residue seems to be of primary impor-
tance in Src SH2 domain binding because affinity is retained
when the nonpolar surface complementarity is reduced.
RESULTS
Semisynthetic Strategy
The semisynthesis relied on a three-fragments strategy where
chemoselective peptide ligations were carried out by native
chemical ligation (NCL) (Dawson and Kent, 2000) (Figure 2; see
Figure S1 available online). The C-terminal aCys peptide
SrcSH2Cys66-106 was prepared by cyanogen bromide (CNBr)
cleavage of a recombinantly derived precursor polypeptide.
The middle peptide (SrcSH2Thz54-65-Bn (benzyl) thioester)
was a 12-mer representing the bD strand of the protein that
harbored residue LysbD3 and was prepared by 9-fluorenylme-
thoxycarbonyl solid-phase peptide synthesis (Fmoc-SPPS).
The N-terminal thioester fragment (SrcSH21-53-MES [mercap-
toethanesulfonic acid] thioester) was prepared by thiolysis of
a recombinant intein fusion (Muir et al., 1998). To assemble these
peptides, we used a strategy based on that first adopted by Kent
and coworkers (Bang and Kent, 2004).
By design, and also to solve some of the issues raised while
setting up the protocol, four mutations were introduced (indi-
cated in green in Figure S1). The native N-terminal Leu residue
(residue 54 or LeuCD7; Figure S1) of SrcSH2Thz54-65-Bn thioester
was mutated to Cys and was protected during the first ligation
reaction as the 1,3-thiazolidine-4-carboxo group (Thz) (Bang
and Kent, 2004). The C-terminal residue of this peptide (residue
65 or AspDE1; Figure S1) was mutated from Asp to Gln because
it has been shown that acidic residues canmediate themigration
of the thioester moiety (Villain et al., 2003). Residue 66 (or
SerDE2; Figure S1) of SrcSH2Cys66-106 was also mutated from
Ser to Cys to allow NCL. All of these sites resided in solvent-
exposed CD and DE loop regions of the domain (Figure 1A)
and had no observable influence on the binding energetics as
determined by calorimetric characterization of a recombinantly
prepared triple mutant Src SH2 domain (data not shown). The
native peptide sequence of SrcSH21-53-MES thioester demon-
strated very poor ligation efficiency due to formation of an
internal thioester (thiolactone) with CysbC3 (residue 42; Fig-
ure S1). Consequently this residuewasmutated to Ser. A SerbC3
mutant has previously been shown to result in a 8-fold increase inr Ltd All rights reserved
Chemistry & Biology
Engineered Src SH2 Domain with Altered Specificityaffinity to the high-affinity pYEEI reference peptide (Bradshaw
et al., 1999). Control experiments verified that this effect on the
binding energetics was reproducible even within the context of
the other Cys and Gln mutations mentioned above.
Chemical Synthesis of SrcSH2Thz54-65 Thioester
Peptides
SrcSH2Thz54-65-Bn thioester harbored the LysbD3 residue
(residue 57) that we wished to modify to unnatural lysyl deriva-
tives andwas prepared by Fmoc-SPPS employingO-(Benzotria-
zol-1-yl)-N,N,N,N0-tetramethyluronium hexafluorophosphate
(HBTU)/1-hydroxybenzotriazole (HOBt) coupling in conjunction
with a sulfamylbutyryl safety-catch linker (Shin et al., 1999).
Alkylation of the linker with iodoacetonitrile followed by treat-
ment with benzyl mercaptan allowed concomitant thioester
generation and cleavage from the resin. Syntheses were carried
out with Fmoc-Lys(Boc)-OH, Fmoc-Orn(Boc)-OH, Fmoc-Dab
(Boc)-OH, or Fmoc-Dap(Boc)-OH to generate the four
SrcSH2Thz54-65-Bn (benzyl) thioester variants at the bD3 position.
All four SrcSH2Thz54-65-Bn (benzyl) thioester variants contained
the 1,3-thiazolidine-4-carboxo group to avoid cyclization.
Peptides were purified to homogeneity by reverse-phase high-
performance liquid chromatography (RP-HPLC) (Figure S2A)
and characterized by electrospray ionization mass spectrometry
(ESI-MS) (Figure S2B).
Preparation of SrcSH2Cys66-106 Peptide
As the length of fragments SrcSH21-53 thioester and
SrcSH2Cys66-106 was near the limit of efficient SPPS (Schnolzer
et al., 1992), we chose to prepare these biosynthetically. This
would also ensure the strategy could be readily adopted by
biological researchers without expertise in chemical peptide
synthesis. We sought to prepare SrcSH2Cys66-106 by treatment
of His6-SrcSH2
54-106 (an available albeit insoluble construct
containing residues 54 to 106 and an N-terminal His6 tag) with
CNBr (which cleaves C-terminal to Met residues) because we
have successfully demonstrated its applicability for the prepara-
tion of insoluble Cys peptides of biosynthetic origin (Macmillan
and Arham, 2004). This necessitated the mutation of the residue
preceding Cys66 to Met. The precursor was purified by dena-
turing Ni2+ affinity chromatography and eluted at pH 4.5. Frac-
tions corresponding to the precursor were further purified by
semipreparative RP-HPLC employing a gradient of 10%–65%
buffer B over 30min with buffer A containing 0.1% trifluoroacetic
acid (TFA) in H2O and buffer B containing 0.1% TFA in MeCN.
The product was lyophilized and dissolved in 80% formic acid
at a concentration of 2.5mgml-1. CNBr (100 Eq.) was then added
and cleavage allowed to proceed for 18 hr at ambient tempera-
ture (Figure S3A). The solvent was removed under reduced
pressure and the residue dissolved in 7.5M guanidinium chloride
(GdmCl). Then 50 mM NaOH and 50 mM DTT were added, and
after 1 min the solution was buffered to pH 8 by addition of
100 mM Na2HPO4 followed by titration with HCl. This procedure
disaggregated the solution and hydrolyzed undesirable formyl
oxyester modifications. To achieve satisfactory separation of
the Cys peptide, a RP-HPLC gradient of 30% aqueous 1:1
isopropanol/MeCN to 60% aqueous 1:1 isopropanol/MeCN
was required (Figure S3B). Furthermore, this gradient system
also allowed SrcSH2Cys66-106 to be purified from a persistentChemistry & Biology 17, 2formyl modification. The peptide could be prepared in satisfac-
tory yield (37%) and of excellent purity (Figure S3C) and its
identity was confirmed by ESI-MS (Figure S3D).
Preparation of SrcSH21-53 Thioester
The N-terminal peptide, SrcSH21-53 thioester, was prepared by
bacterial expression of the first 53 residues of the Src SH2
domain fused to a splicing defective mutant of the GyrA intein
from Mycobacterium xenopi. For that purpose, the SrcSH21-53
gene fragment was cloned in the pTXB1 vector (NEB). Chitin-
affinity purification followed by sodium mercaptoethanesulfo-
nate (MESNa) treatment in phosphate buffered 2 M urea at
pH 6 enabled cleavage and generation of SrcSH21-53 thioester
with excellent efficiency (>95%) as evaluated by SDS-PAGE
(Figure S4A). Elution of the peptide was carried out in phosphate
buffered 6 M urea at pH 6. Solid urea was added to the pooled
fractions to a final concentration of 8 M followed by concentra-
tion. Disaggregation of the peptide required the addition of
organic cosolvent (30% MeCN) and acidification with 1% TFA.
The peptide was then further purified by RP-HPLC using stan-
dard conditions (Figure S4B) and its identity verified by ESI-MS
(Figure S4C). The SrcSH21-53 thioester peptide was obtained in
good yield of 2–2.2 mg per 1 l culture medium.
Native Chemical Ligation 1
Once peptides were in hand, the SrcSH2Cys66-106 thioester was
coupled to the synthetic SrcSH2Thz54-65-Bn thioester containing
the desired lysyl derivative by NCL in a ratio of 1:1.2, and moni-
tored to completion by analytical RP-HPLC (Figure 3). Ligation
under denaturing conditions (sodium phosphate buffer at pH
6.9–7.2 containing 7.5 M guanidinium chloride [GdmCl], 100 mM
mercaptophenylacetic acid [MPAA] and 60 mM tris [2-carbox-
yethyl] phosphine [TCEP]) was 95% complete after 3 hr and
conversion of the N-terminal 1,3-thiazolidine-4-carboxo group
to Cys was achieved by direct addition of 200 mM methoxyl-
amine hydrochloride (MeONH2dHCl) (Figure 3). The pH was
adjusted to 4 and deprotection left to proceed overnight. The
SrcSH2Cys54-106 product was purified in 61% yield by semipre-
parative RP-HPLC (23%–48% buffer B; buffer B = 0.1% TFA
in MeCN). Fractions containing the peptide were verified by
ESI-MS.
Native Chemical Ligation 2 and Protein Folding
Native chemical ligation between SrcSH2Cys54-106 and
SrcSH21-53-MES thioester was also carried out under denaturing
conditions in a buffer (300 mM HEPES [pH 7.5], 7.5 M GdmCl,
60 mM MPAA, 60 mM TCEP) containing 15% acetonitrile as
organic cosolvent. Cosolvent was necessary otherwise
SrcSH21-53-MES thioester peptide had a high propensity to
aggregate, presumably due to b sheet formation as the peptide
encompasses a b sheet-rich region of the SH2 domain.
However, when ligations were carried out in this buffer, over
time the mass of unreacted SrcSH2Cys54-106 was found to
increase by 42 Da as detected by ESI-MS and the ligation would
stall. When the reaction was treated with a higher concentration
of thiol (200mMMESNa), the increasedmass of SrcSH2Cys54-106
was still observed. From these observations we deduced that
SrcSH2Cys54-106 was becoming irreversibly modified at the N
terminus. An explanation is that reaction with isocyanic acid74–284, March 26, 2010 ª2010 Elsevier Ltd All rights reserved 277
Figure 4. Representative Ligation between SrcSH2Cys54-106 (OrnbD3)
and SrcSH21-53-MES Thioester Monitored by Analytical RP-HPLC
(A) Reaction at t = 5 min. Two peaks at tR = 22.5 and 26.0 min correspond to
SrcSH21-53-MES thioester and in situ generated MPAA thioester, respectively.
Peak at tR = 37.6 min corresponds to SrcSH2
Cys54-106.
(B) Reaction at t = 90 min. Peak at tR = 38.6 min corresponds to SrcSH2
1-106.
(C) RP-HPLC purified SrcSH21-106 and ESI-MS characterization (inset).
Observed mass = 12,288.0 Da; expected = 12,287.9 Da.
Figure 3. Representative Ligation between SrcSH2Cys66-106 and
SrcSH2Thz54-65-Bn Thioester Monitored by Analytical RP-HPLC
(A) Reaction at t = 5 min. Two peaks at tR = 18.2 and 22.4 min correspond to
SrcSH2Thz54-65-Bn thioester and in situ generated MPAA thioester,
respectively. Peak at tR = 30.9 min corresponds to SrcSH2
Cys66-106.
(B) Reaction at t = 3 hr. Peak at tR = 30 min corresponds to SrcSH2
Thz54-106.
(C) The purified and deprotected ligation product SrcSH2Cys54-106. Inset is an
ESI-MS spectrum confirming deprotection to Cys for the OrnbD3 incorpora-
tion. Observed mass = 6093.8 Da; theoretical = 6094.1 Da.
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Engineered Src SH2 Domain with Altered Specificitywas giving rise to carbamylation (+43 Da). Isocyanic acid is
a product of urea degradation, and because the SrcSH21-53
thioester was treated with urea for prolonged periods, such a
side reaction seems plausible. Analysis of the isolated
SrcSH2Cys54-106 peptide in the MeCN-containing buffer by
RP-HPLC showed that the modification was occurring at a rate
comparable to that of MPAA catalyzed chemical ligation. In
subsequent reactions we simply used SrcSH21-53-MES thioester
in a 1.5 fold excess and incubated it for 1 hr in ligation buffer
prior to addition of the Cys peptide. This ensured the majority
of the thioester peptide had undergone exchange with MPAA,
which has been shown to be rate limiting in aNCL reaction (John-
son and Kent, 2006). This allowed ligations to be carried out to
80% completion in 1.5 hr with minor loss of SrcSH2Cys54-106278 Chemistry & Biology 17, 274–284, March 26, 2010 ª2010 Elseviethrough carbamylation (Figure 4). Importantly, none of the
purified full-length SrcSH21-53 polypeptide was found to be
modified.
The full-length SrcSH21-106 polypeptide was purified by semi-
preparative RP-HPLC and lyophilized with a yield of 21% for the
NCL reaction. Masses for the syntheses of the 4 SH2 domain
derivatives (termed ‘‘Src SH2 Lysb3, OrnbD3, DabbD3, or
DapbD3 domains’’) were determined by ESI-MS (Figure 5;
Figures S5A and S5B). The proteins were folded by slow
drop-wise addition while stirring into 10 volume equivalents of
ITC buffer (see details in Experimental Procedures). Folded
proteins were further analyzed by SDS-PAGE (Figure S6). The
yield of the refolding process was 70% and the total yield of
folded material based on the starting peptide (SrcSH2Cys66-106)
was 9%. The raw calorimetric data and binding isotherms for
all the interaction studies are presented in Figure 6. The thermo-
dynamic parameters are summarized in Table 1.r Ltd All rights reserved
Figure 5. Deconvoluted ESI-MS Spectra
of the Purified Src SH2 Variants
(A) Src SH2(LysbD3), expectedmass = 12,301.9Da.
(B)SrcSH2(OrnbD3), expectedmass= 12,287.9Da.
(C)SrcSH2(DabbD3),expectedmass=12,273.9Da.
(D)SrcSH2(DapbD3),expectedmass=12,259.9Da.
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The calorimetric data for the reference pYEEI peptide binding to
the semisynthetic Src SH2 LysbD3 domain (which, as indicated
above, contains four mutations [indicated in green in Figure S1])
were in excellent agreement with those obtained for the
recombinant CysbC3Ser Src SH2 domain (Bradshaw et al.,
1999), thus indicating that themethodology produced a correctly
folded protein with full binding potential. Raw calorimetric data
and integrated binding isotherms are shown in Figure 6. As
expected, conservative replacement of LysbD3 with OrnbD3
produced a Src SH2 domain with similar affinity and thermody-
namic signature. However, there was a modest 1.2-fold im-
provement in affinity attributable to an increase in TDS compen-
sating for a reduced DH relative to LysbD3. This trend was more
pronounced for pYEEI binding to the Src SH2 DabbD3 domain.
Binding affinity was reduced 2-fold as a result of a reduction in
DH from 7.5 to 5.3 kcal mol-1 despite an associated increase
in TDS from 2.3 kcal mol-1 to 4.0 kcal mol-1. A possible explana-
tion for this observation is that the reduced side-chain length of
the bD3 residue compromises the geometry of the electrostatic
interaction of the g-amino group with the carboxylate of
+1-Glu. Such observations are difficult to assign, but because
the carboxylate of +1 Glu is now presumably forming a weaker
interaction, and the g-amino group would now be positioned
such that it is in proximity of the aliphatic component of the +1
Glu residue, it may increase mobility. Intrigued by the capacity
of the DabbD3 to reduce the binding free energy for the pYEEI
peptide, we characterized the binding event of the Src SH2
DabbD3 domain to the pYDEI peptide. Gratifyingly, weChemistry & Biology 17, 274–284, March 26, 2010observed a 5-fold enhancement in
binding affinity compared with Src SH2
DabbD3 binding to pYEEI and rescue of
the thermodynamic signature obtained
with Src SH2 LysbD3 domain binding
to the pYEEI peptide (TDS reduced to
2.5 kcal mol-1 but a much more favorable
DH of7.6 kcalmol-1). In fact, affinity was
2-fold higher than semisynthetic Src
SH2 LysbD3 binding to the pYEEI
peptide, making this interaction the tight-
est binding Src SH2 domain interaction
with a singly phosphorylated peptide to
date. To verify that the enhanced affinity
for pYDEI was directly attributable to
DabbD3, we characterized pYDEI bind-
ing to a recombinant Src SH2 LysbD3
domain containing all four ‘‘ligation’’
mutations (indicated in green in Figure S1;
these are the mutations referred to above
that were required for the design of thesynthetic Src SH2 domains described here). We have shown
that this quadruple mutant recapitulates the binding properties
of the synthetic LysbD3 SH2 domain and thus constitutes a valid
source of material for the experiment we wished to conduct.
Binding affinities of this quadruple Src SH2 domain mutant for
the pYDEI or pYEEI peptides were found to be similar
(Figure S7; Table 1), in accordance with previous data obtained
on the wild-type SH2 domain where no difference in affinity was
observed between pYEEI and pYDEI binding (Bradshaw and
Waksman, 1999). Thus, enhanced affinity of the Src SH2
DabbD3 domain for the pYDEI peptide is indeed due to the
presence of Dab at the bD3 position of the SH2 domain. Mech-
anistically it is difficult to explain the reduced affinity for pYEEI
but retained affinity for pYDEI. However, as the DabbD3:pYDEI
interaction is strongly enthalpic, we hypothesize that the
g-amino group of DabbD3 forms a more idealized interaction
geometry with the carboxylate of +1 Asp relative to +1 Glu
present in pYEEI. This may be augmented by the fact that the
g-amino group is too short to interact with AspCD2 and as
such is not conformationally dictated by this residue. Because
the +1 Asp side chain is shorter, the g-amino group would be
less likely to clash with the aliphatic component of +1 Asp, which
would help to ascribe the reduced TDS observed with pYDEI
relative to pYEEI. Other factors such as facilitation of solvent
coordination may also be at play. The binding of pYEEI and
pYDEI to semisynthetic SH2 domains incorporating DapbD3
were also characterized. The Src SH2 DapbD3 domain had
a striking 16-fold reduction in affinity for the pYEEI peptide attrib-
utable to a reduced DH and no significant compensatory TDS asª2010 Elsevier Ltd All rights reserved 279
Figure 6. ITC Binding Isotherms for pYEEI and pYDEI Peptide Binding to Semisynthetic SH2 Domains
(A) Semisynthetic Src SH2(LysbD3) domain titration against pYEEI reference peptide.
(B) Semisynthetic Src SH2(OrnbD3) domain titration against pYEEI reference peptide.
(C) Semisynthetic Src SH2(DabbD3) domain titration against pYEEI reference peptide.
(D) Semisynthetic Src SH2(DabbD3) domain titration against pYDEI peptide.
(E) Semisynthetic Src SH2(DapbD3) domain titration against pYEEI reference peptide.
(F) Semisynthetic Src SH2(DapbD3) domain titration against pYDEI peptide.
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of the b-amino group of Dap would be 8.1 such that only 80%
of the amine would be protonated at the experimental pH of 7.5.
This is in contrast to the other derivatives, which would be > 99%
protonated. Therefore, reduced affinity for the DapbD3 analog
may also be attributable to partial amine protonation reducing
the capacity to form electrostatic interactions. It should also be
noted that short diamino acids such as Dap are prone to N-N
acyl shifts, which would perturb the protein backbone and may
account for the observed low affinity. However, based on the
sharp peaks we obtained after HPLC purification of all the
synthetic peptides (Figure S2A), we conclude that such rear-280 Chemistry & Biology 17, 274–284, March 26, 2010 ª2010 Elsevierangements were not occurring. Binding of the Src SH2 DapbD3
domain to pYDEI is improved compared with pYEEI, due to
a more favorable DH of binding. However, TDS was now the
lowest of all of interactions characterized. This may be due to
the DapbD3 side chain being too short to influence the confor-
mational flexibility of the phosphopeptide residue.
DISCUSSION
A system has been developed allowing the semisynthesis
of the Src SH2 domain from three peptide fragments. The
methodology as described herein allows unnatural amino acidr Ltd All rights reserved
Table 1. Thermodynamic Data for pYEEI and pYDEI Binding
to the Semisynthetic SH2 Domains
SH2 Domain Ligand
Kd
(nM)
DG
(kcal mol-1)
DH
(kcal mol-1)
TDS
(kcal mol-1)
LysbD3 pYEEI 63 9.8 7.5 2.3
LysbD3a pYDEI 70 9.7 7.7 2.1
OrnbD3 pYEEI 54 9.9 7.2 2.7
DabbD3 pYEEI 163 9.2 5.3 4.0
DabbD3 pYDEI 35 10.2 7.6 2.5
DapbD3 pYEEI 990 8.2 5.4 2.8
DapbD3 pYDEI 398 8.7 7.3 1.4
aData collected for a recombinant quadruple ‘‘ligation’’ mutant Src SH2
domain.
Chemistry & Biology
Engineered Src SH2 Domain with Altered Specificityincorporation into the bD strand of the protein as the peptide
representing this component was synthesized chemically.
However, further reliance on SPPS could in principal be adopted
to incorporate unnatural amino acids at any site of the protein.
To resolve ambiguities associated with the LysbD3 residues
role in phosphopeptide specificity, and to try and prepare Src
SH2 domain analogs with altered specificity, we incorporated
unnatural lysyl derivatives with progressively shorter side chains
at this position. Following a hypothesis-driven line of investiga-
tion, we incorporated the lysyl derivatives Orn, Dab, and Dap
at the bD3 position. The Src SH2 DabbD3 and DapbD3 domains
bound to the pYEEI reference peptide with a 2.5- and 16-fold
reduction in affinity, respectively. However, the DabbD3 analog
demonstrated a 5-fold preference for pYDEI versus pYEEI.
Also, DabbD3:pYDEI interaction is twice as strong as the
reference LysbD3:pYEEI interaction. It is thus the first time that
a change in specificity resulting in an affinity higher than the
one observed for the reference interaction is observed. The
change is admittedly small but all perturbations (except for
dephosphorylation) brought to the Src SH2 domain have been
shown to have only small incremental effects. The data illustrate
how high-affinity interaction at the +1 interface of the Src SH2
domain seems to be governed by the geometry of the electro-
static interaction between the lysyl bD3 residue and the +1
phosphopeptide residue. Owing to the various biological
tyrosine phosphorylated substrates that have Glu and Asp at
the +1 position (Table S1), the semisynthetic Src SH2 DabbD3
domain prepared as described herein may have application as
a research tool by competing favorably with +1 Asp-containing
phosphorylated Src SH2 domain substrates. Although not tested
due to difficulties in preparing sufficient material, altered and
desirable specificity changes may also exist with other +1
residues, such as hydrophobic amino acids that exist in bio-
logically relevant Src SH2 domain targets. Further optimization
may provide access to higher affinity Src SH2 domains with
altered specificities, which could be further modified thus
improving the pharmacokinetic profile and yielding protein
therapeutics.
SIGNIFICANCE
Presented herein are to our knowledge the first examples
of biophysically characterizing the significance of the lengthChemistry & Biology 17, 2of the aliphatic component of the lysine side chain in macro-
molecular recognition, and reengineering of the prototype
interactionmodule, the Src SH2 domain, such that it demon-
strates altered specificity. The methodology adopted is
within reach of biologists and shows that challenging
peptide sequences, compatible with chemical ligation, can
be prepared with recombinant DNA technology. Studies
have been conducted with the lysyl derivatives discussed
within, but only with regard to their involvement in
intrahelical interactions (Cheng et al., 2007). It was found
that intrahelical Lys-Glu pairing resulted in a low-energy
conformer that could not be adopted with Orn-, Dab-, or
Dap-Glu interactions, and these observations were taken
as partial reasoning for the natural selection of the lysine
amino acid. Within the Src SH2 domain, LysbD3 does not
partake in intrahelical interaction so the role of the lysyl
derivatives in this study has been elucidated with regard to
protein-ligand recognition only. Because it has been demon-
strated that the affinity of an interaction involving Lys can be
enhanced by replacing it with Dab, it seems as though
nature’s choice for this residue is more convoluted. The
lysine side chain is subject to a myriad of posttranslational
modifications such as ubiquitination, SUMOylation, acetyla-
tion, and mono-, di-, and tri-methylation, to name but a few.
The Lys side chain ensures the amino group is positioned
further from the protein backbone than the other derivatives
and also confers flexibility. The significance of these traits
in the ability of posttranslational modifications to be
performed by ubiquitin ligases, acetylases, and deacety-
lases, for example (Seet et al., 2006), may facilitate dynamic
posttranslational modification as the amino nucleophile
is less hindered and can adopt more conformations for
recognition.
EXPERIMENTAL PROCEDURES
Preparation of SrcSH2Cys66-106
The cDNA corresponding to residues 197-249 (Swiss-Prot ID P63185) was
amplified by polymerase chain reaction (PCR) using the forward 50-C ACC
GAG AAT TTA TAC TTC CAA TGC AAT GTG AAG CAC TAC AAG ATC CGC
AAG CTG-30 primer and the reverse 50-TTA CGT GGG GCA GAC GTT GGT
CAGGCG-30 primer. This allowed directional cloning into the pET151-D vector
(Invitrogen) in accordance with the manufacturers protocol. Residues 208 and
209 were subsequently mutated to Met and Cys, respectively, by QuikChange
mutagenesis using the forward 50-C TAC AAG ATC CGC AAG CTG ATG TGC
GGC GGC TTC TAC ATC ACC-30 primer and the reverse 50-GGT GAT GTA
GAA GCC GCC GCA CAT CAG CTT GCG GAT CTT GTA G-30 primer. Correct
cloning was confirmed by DNA sequencing. Plasmid DNA was transformed
into BL21-AI cells (Invitrogen) and a transformant used to inoculate an
overnight Luria-Bertani (LB) starter culture supplemented with ampicillin
(100 mg ml-1). The culture was diluted 3:100 with fresh LB media (1 l) supple-
mented with ampicillin (100 mg ml-1). Cells were grown to mid-log phase
at 37C and induced with L-arabinose (0.2%) and IPTG (0.5 mM). After 3 hr
the cells were harvested, suspended in lysis buffer (20 mM Tris [pH 7.4],
500mMNaCl), and lysedwith a cell disruptor (Avestin). The lysate was clarified
by centrifugation (39,0003 g, 30min) and the pellet dissolved in binding buffer
(100 mM Tris, 100 mMNaH2PO4 [pH 8], 6 M GdmCl) supplemented with 2 mM
DTT and stirred for 2 hr. The suspension was then clarified by centrifugation
(45,000 3 g, 30 min) and the supernatant loaded onto a 5 ml Ni-NTA column
(QIAGEN). The column was washed with 10 volumes of binding buffer and
the polypeptide eluted with elution buffer (100 mM Tris, 100 mM NaH2PO4
[pH 4.5], 6 M GdmCl). Fractions corresponding to the polypeptide were brown
in color and were pooled and desalted by multiple semipreparative RP-HPLC74–284, March 26, 2010 ª2010 Elsevier Ltd All rights reserved 281
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applied over 25 min at a flow rate of 4.7 ml min-1. Buffer A = 0.1% TFA in
H2O, Buffer B = 0.1% TFA in MeCN. Fractions were combined and analyzed
by ESI-MS (observed mass = 10,661.2; expected mass = 10,660.2). The
pool was then lyophilized yielding 25 mg l-1 culture medium. The peptide
was dissolved in nitrogen saturated 80% aqueous formic acid at a concentra-
tion of 2.5 mg ml-1. In a fume hood, 100 molar equivalents of solid CNBr were
added and the reaction left to stir under nitrogen with the exclusion of light for
18 hr. Solvent was then removed under reduced pressure and the residue
dissolved in 7.5 M GdmCl at a concentration of 2.5 mg ml-1. The solution
was basicified by addition of NaOH (50 mM) and stirred for 1 min. Solid DTT
(50 mM) was then added and the solution mixed 10:1 with 200 mM Na2HPO4,
7.5MGdmCl. The solution was titrated topH 8 by careful addition of 5MHCl.
The target peptide was then purified by multiple semipreparative RP-HPLC
runs using a gradient of 30%–60% buffer B, with an initial 5 min isocratic
phase, over 20min at a flow rate of 4mlmin-1. Buffer B = 0.1%TFA in 1:1MeC-
N:isopropanol. Fractions corresponding to SrcSH2Cys66-106 were determined
by ESI-MS and lyophilized (observed mass = 4581.9; expected mass =
4582.2). The yield of peptide was 4 mg l-1 culture and the yield from the
cleavage reaction was 37%.
Preparation of SrcSH21-53-MES Thioester
The cDNA corresponding to residues 144–196 (Swiss-Prot ID P63185) were
amplified and PCR cloned using the forward 50-G GAA TTC CAT ATG CAG
GCT GAG GAG TGG TAC TTT GGG-30 primer and the reverse 50-GGT GGT
TGCTCTTCCGCACCCCTTGGCGTTGTCAAAGTC-30 primer and the reac-
tion was then treated with DpnI (20 U) for 1 hr at 37C. The insert DNA and
pTXB1 vector were double digested with NdeI and SapI restriction enzymes.
The digested vectorwas subsequently treatedwith calf intestinal phosphatase.
Both insert and vector were spin column purified and ligated using T4-Ready-
to-go DNA ligase (Invitrogen). Colony PCR and DNA sequencing verified
correct cloning. Plasmid DNA was then used to transform ER2566 cells
(NEB) and a transformant used to inoculate an overnight LB starter culture sup-
plementedwith ampicillin (100 mgml-1). The culture was then diluted 3:100with
fresh Terrific broth medium (2 l) supplemented with glycerol (0.8% v/v) and
ampicillin (100 mg ml-1). Cells were grown to mid-log phase and induced with
IPTG (0.1 mM) and expression left to commence overnight at 16C. Cells
were harvested and suspended in 100 ml ice-cold buffer (50 mM Na2HPO4/
NaH2PO4 [pH 7.5], 500 mM NaCl, 5 mM EDTA, 0.1% v/v Triton X-100,
0.5mMPMSF, protease inhibitor, Roche). Cells were lysedwith a cell disruptor
andclarifiedbycentrifugation (39,0003g, 30min). Theclarified lysatewas then
incubated with chitin beads (20 ml) pre-equilibrated with lysis buffer at 4C on
a shaker for 2–3 hr. The slurry was then centrifuged (1003 g, 1 min), superna-
tant discarded and the beads transferred to an empty XK-26 column (GE Life
Sciences). The column was washed with 10 volumes of wash buffer
(Na2HPO4/NaH2PO4pH7.5, 500mMNaCl, 1mMEDTA) and thenwith 1column
volume of 20 mM Na2HPO4 pH 6, 6 M urea, 500 mM NaCl, 1 mM EDTA. The
column was equilibrated with 1 column volume of 20 mM Na2HPO4 pH 6,
2 M urea, 500 mM NaCl, 1 mM EDTA followed by 3 column volumes of the
same buffer supplemented with MESNa (100 mM). The flow was stopped
and the column left to incubate for 3 nights. Alternatively, the bufferwas supple-
mented with MESNa (200 mM) and left for 1 night. The thioester peptide was
then eluted with 20 mM Na2HPO4 pH 6, 6 M urea, 500 mM NaCl, 1 mM
EDTA. Fractions containing the polypeptide and cleavage efficiency (>95%)
were determined by SDS-PAGE. Solid urea was then added to the combined
fractions to a final concentration of 8 M. The peptide was concentrated
with an Amicon centrifugal filter unit, 3 kDa cutoff (Millipore) to 5ml. Acetonitrile
was then added to a final concentration of 30% followed by 1% TFA. The solu-
tion was filtered and purified by semipreparative RP-HPLC using a gradient of
20 - 60%bufferBover 20min,with a5min isocratic phaseandaflow rate of 4ml
min-1. Buffer A = 0.1% TFA in H2O, Buffer B = 0.1% TFA in MeCN. Fractions
corresponding to SrcSH21-53-MES thioester were determined by ESI-MS
(observed mass = 6350.2; expected mass = 6350.1). The peptide was then
lyophilized yielding 4 mg from 2 l culture.
Chemical Synthesis of SrcSH2Thz54-65-Bn Thioester
Peptide synthesis was conducted on a 0.1 mmol scale using an Applied
Biosystems 433A peptide synthesizer operating the Fastmoc protocol282 Chemistry & Biology 17, 274–284, March 26, 2010 ª2010 Elsevie(HBTU/HOBt, DIPEA) using NMP as solvent. 4-sulfamylbutyryl Novasyn TG
resin (loading = 0.23 mmol g-1) preloaded with NH2-Gln(Trt)-OH (Novabio-
chem) was used to prepare the sequence NH2-NVXHYKIRKLQ-resin, where
X = Lys, Orn, Dab, or Dap. Amino acids were coupled for 0.5 hr and V and I
were double coupled. Following automated synthesis the resin was trans-
ferred to a manual synthesis vessel. Boc-Thz-OH (117 mg, 0.5 mmol) was
weighed into a vial and dissolved in anhydrous DMF (1.0 ml). To this solution
was added a 0.45 M solution of HBTU/HOBt in anhydrous DMF (1.1 ml)
followed by DIPEA (0.15 ml) while stirring. This solution was then transferred
to the manual synthesis vessel which was subsequently capped and shaken
(250 rpm) at room temperature for 2 hr. The reaction vessel was washed
extensively with DMF and DCM. The dry resin was transferred to a vial and
anhydrous DMF (4.0 ml) was added followed by DIPEA (300 ml) and iodoace-
tonitrile (300 ml). The reaction was stirred for 36 hr at room temperature with
the exclusion of light. The alkylated resin was washed with DMF then DCM
and resuspended in anhydrous DMF (4.0 ml). Benzylmercaptan (300 ml) was
added followed by benzenethiol, sodium salt (5 mg). The resin was stirred at
room temperature for 24 hr after which time the resin was filtered off and
washed extensively with DMF then DCM. The solvent was removed under
reduced pressure and the residue exposed to 95% v/v TFA, 2.5% v/v ethane-
dithiol, 2.5% v/v H2O (4.0 ml) for 5 hr. The crude product was then precipitated
and washed with cold diethylether. The crude peptide was dissolved in 20%
aqueous MeCN and lyophilized yielding 40 mg of crude peptide per
synthesis, which was of >75% purity and stored at 20C. Peptide was
purified as required by semipreparative RP-HPLC by applying a gradient
of 5%–45% Buffer B over 30 min. Buffer A = 0.1% TFA in H2O, Buffer
B = 0.1% TFA in MeCN.
Native Chemical Ligation 1
SrcSH2Cys66-106 (4mg, 0.87 mmol) was dissolved in a 1.14ml degassed ligation
buffer (200mMNa2HPO4 [pH6.9], 7.5MGdmCl, 100mMMPAA, 60mMTCEP).
To facilitate dissolution the sample was sonicated. The SrcSH2Thz54-65-Bn
thioester peptide (1.69 mg, 1.04 mmol) with the desired lysyl derivative was
then added. The reaction wasmonitored to completion by analytical RP-HPLC
using 5 ml samples of the ligationmixture quenched with 3% TFA. A gradient of
15%–45% B was applied over 30 min with an initial 5 min isocratic phase.
Mobile phase B = 0.1% TFA in MeCN. Solid MeONH2$HCl was then added
to a concentration of 200 mM and the pH was adjusted to 4 on ice by careful
addition of 8 MHCl. Deprotection was left to commence overnight. The depro-
tected ligation product was purified by semi-preparative RP-HPLC. A gradient
of 23%–48% B was applied, with a 5 min isocratic stage and at a flow rate of
3 ml min-1. Fractions containing SrcSH2Cys54-106 were confirmed by ESI-MS
(representative observed mass for LysbD3 peptide = 6093.8; expected
mass = 6094.1). The recovered yield of lyophilized peptide was 61%
(3.55 mg). This procedure was repeated for the three other lysyl derivatives.
Native Chemical Ligation 2
SrcSH21-53-MES thioester (3.5 mg, 0.55 mmol) was dissolved in 0.92 ml
solvent consisting of 85% buffer (300 mM HEPES [pH 7.5], 7.5 M GdmCl,
60 mM MPAA, 60 mM TCEP) and 15% MeCN. The peptide was left to
transthioesterify for 30 min. SrcSH2Cys54-106 (2.25 mg, 0.37 mmol) containing
the desired lysyl derivative was then added. The reaction was monitored
by analytical RP-HPLC using 10 ml samples quenched with 3% TFA.
A gradient of 25%–40% B over 45 min with an initial 5 min isocratic phase
was applied. Buffer A = 0.1% TFA in H2O, Buffer B = 0.1% TFA in MeCN.
The ligation product (SrcSH21-106) was purified by semi-preparative
RP-HPLC applying the same gradient at 4 ml min-1. Isopropanol was imme-
diately added to the fractions at a final concentration of 10% and fractions
containing the peptide were determined by ESI-MS and lyophilized. Src
SH2(LysbD3), expected mass = 12301.9 Da, observed = 12302.4 Da; Src
SH2(OrnbD3), expected mass = 12287.9 Da, observed = 12288.0 Da;
Src SH2(DabbD3), expected mass = 12273.9 Da; observed = 12274.1 Da;
Src SH2(DapbD3), expected mass = 12259.9 Da, observed = 12260.1 Da. The
recovered yield of the SrcSH21-106 lyophilized peptides was 21% (0.96 mg).
Protein Folding
Lyophilized SrcSH21-106 was dissolved in degassed buffer (20 mM HEPES
[pH 7.5], 7.5 M GdmCl, 20 mM 2-mercaptoethanol, 1 mM EDTA) atr Ltd All rights reserved
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volume equivalents of ITC buffer (20 mMHEPES [pH 7.5], 100 mMNaCl, 5 mM
2-mercaptoethanol, 1 mM EDTA) while stirring. The protein was then dialyzed
overnight against ITC buffer (1 l) at 4C using a 6 – 8 kDa cut-off membrane
(Spectrum Labs). The protein was then centrifuged (20,000 3 g, 20 min) and
the supernatant concentrated to 25 mM with a 10 kDa cut-off centrifugal
spin filter (Millipore). The protein was then dialyzed against fresh ITC buffer
(1 l) using a 500 Da cut-off Float-a-lyzer (Spectrum Labs). The pYEEI or pYDEI
peptide was dissolved at a concentration of 0.5 mM in ITC buffer and dialyzed
in parallel against the same buffer for 48 hr at 4C. Folding efficiency was 70%
yielding 0.7 mg of protein per synthesis.Isothermal Titration Calorimetry
ITC experiments were carried out with a VP-ITCmicrocalorimeter (Microcal) as
previously described. Experimental protein concentrations were 16–20 mM
and peptide concentrations were 0.2–0.3 mM. Protein and peptide concentra-
tions were determined by electronic spectroscopy using extinction coeffi-
cients of 14,700 M-1 (280 nm) and 695 M-1 (268 nm), respectively. Phospho-
peptides consisted of the sequence Ac-PQpYXEIPI-NH2 (where X = E or D)
and were obtained at > 95% purity (Biosynthesis Inc., TX, USA). Titrations
were carried out at 25C using 8–11 ml injections. This resulted in a 3-fold
excess of peptide, which allowed the enthalpy of ligand dilution to be deter-
mined from the mean average of the injections after protein saturation. Data
were fitted with the VP-ITC routine within the ORIGIN software using the single
site model. Stoichiometry, n, for all titrations was 0.8–1.1.SUPPLEMENTAL INFORMATION
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